Uwe Platzbecker, MD, discusses the FDA approval of luspatercept for the treatment of anemia in patients who have not had prior treatment with erythropoiesis-stimulating agent and may require regular red blood cell transfusions could change the sequencing of agents for this patient population.
Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found.
A recent study suggests that patients with myelodysplastic syndrome (MDS) could potentially benefit from allogeneic hematopoietic cell transplantation (HCT) regardless of genetic mutation status.
The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis stimulating agent (ESA) use in adult patients with very low– to intermediate-risk myelodysplastic syndrome (MDS) who may require regular red blood cell (RBC) transfusions.